Tag: genomics (page 2 of 2)

how camels survive in the desert

An Arabian Camel

Genomic studies are helping researchers determine what is unique about these dessert dwelling mammals. It turns out it is mostly their metabolism. From Scientific American:

Camels, as ruminants like cattle and sheep, digest food by chewing the cud. But many of the Bactrian genome’s rapidly evolving genes regulate the metabolic pathway, suggesting that what camels do with the nutrients after digestion is a whole different ball game. “It was surprising to me that they had significant difference in the metabolism,” says Kim Worley, a molecular geneticist at Baylor College of Medicine in Houston, Texas. The differences could point to how Bactrians produce and store energy in the desert.

The work shows that camels can withstand massive blood glucose levels owing in part to changes in genes that are linked to type II diabetes in humans. The Bactrians’ rapidly evolving genes include some that regulate insulin signaling pathways, the authors explain. A closer study of how camels respond to insulin may help to unravel how insulin regulation and diabetes work in humans. “I’m very interested in the glucose story,” says Brian Dalrymple, a computational biologist at the Queensland Bioscience Precinct in Brisbane, Australia.

The researchers also identified sections of the genome that could begin to explain why Bactrian camels are much better than humans at tolerating high levels of salt in their bloodstreams. In humans, the gene CYP2J controls hypertension: suppressing it leads to high blood pressure. However, camels have multiple copies of the gene, which could keep their blood pressure low even when they consume a lot of salt, suggest the authors of the latest work.

The study appears in Nature Communications.

are we near drug treatments for lung cancer?

Exciting news from the New York Times regarding drug treatments for certain lung cancers:

The first large and comprehensive study of the genetics of a common lung cancer has found that more than half the tumors from that cancer have mutations that might be treated by new drugs that are already in the pipeline or that could be easily developed.

For the tens of thousands of Americans with that cancer — squamous cell lung cancer — the results are promising because they could foretell a new type of treatment in which drugs are tailored to match the genetic abnormality in each patient, researchers say.

“This is a disease where there are no targeted therapies,” said Dr. Matthew Meyerson of the Dana-Farber Cancer Institute in Boston, referring to modern drugs that attack genetic abnormalities. He is a lead author of a paper on the study, with more than 300 authors, which was published online in the journal Nature on Sunday.

“What we found will change the landscape for squamous cell carcinoma,” Dr. Meyerson said. “I think it gives hope to patients.”

The study is part of the Cancer Genome Atlas, a large project by the National Institutes of Healthto examine genetic abnormalities in cancer.

Read the original Nature paper here.

links!

Check these babies out:

  1. Michael Snyder examines his own genome and proteomics to gain insight on diabetes.
  2. Fruit flies hit the sauce when rejected sexually and its all to do with neuropeptide F.
  3. Dow & DuPont have new seeds with lower trans-fat content.
  4. This is fun! 7-year old kid builds a monster trapping Rube Goldberg machine.
  5. A new fluorescent sensor for cell metabolites is based on RNA instead of protein.
  6. Lasers can be used as lightning rods.
  7. Contemplating the size of the universe.
//thaudray.com/4/4535925